THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED

Clinical trials for THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED explained in plain language.

Never miss a new study

Get alerted when new THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED trials appear

Sign up with your email to follow new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Custom treatment could reduce drug use in dangerous blood clotting disease

Disease control Terminated

This study tested whether doctors could personalize the dose of a blood-clotting disorder medication (caplacizumab) based on regular blood tests. It involved 58 adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and serious condition. The goal was to see if u…

Matched conditions: THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED

Phase: PHASE2 • Sponsor: University Hospital, Rouen • Aim: Disease control

Last updated Mar 30, 2026 14:28 UTC

THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED

Get alerted when new THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED trials appear

Custom treatment could reduce drug use in dangerous blood clotting disease